Table 1.

Baseline Characteristics of Study Population. Results are Presented as Numbers (With %) or Median (With Interquartile Range).

	Cohort A (n = 204)	Cohort B (n = 81)	p value∗	Cohort C (n = 23)	p value†
Age (years)	51 (36–62)	64 (54–75)	< 0.001	58 (52–68)	0.029
Gender (male)	67 (32.8%)	53 (65.4%)	< 0.001	15 (65.2%)	0.008
Event of death	0	14 (17.3%)		0
No oxygen	204 (100%)	8 (19.5%)		23 (100%)
Lowflow therapy		40 (49.4%)
Highflow therapy		12 (14.8%)		0
Invasive ventilation		21 (25.9%)
ARDS
mild	0	5 (6.2%)		0
moderate	0	15 (18.5%)		0
severe	0	13 (16.0%)		0
Treatments
no treatment	204 (100%)	0		23 (100%)
antibiotic/antifungal treatment		81 (100%)
maraviroc		48 (59.3%)
hydroxychloroquine		52 (65%)
anakinra		6 (7.4%)
tocilizumab		4 (4.9%)
immunoglobulines (IVIG)		6 (7.4%)
plasmapheresis		3 (3.7%)
cytosorb®		2 (2.5%)
convalescent serum		2 (2.5%)

^∗Comparison of p values between cohort A and B.

^†Comparison of p values between cohort A and C.